Vigil Neuroscience, Inc. (NASDAQ:VIGL) Short Interest Update

Vigil Neuroscience, Inc. (NASDAQ:VIGL - Get Free Report) was the recipient of a significant drop in short interest in February. As of February 15th, there was short interest totalling 1,020,000 shares, a drop of 43.6% from the January 31st total of 1,810,000 shares. Approximately 5.2% of the company's stock are sold short. Based on an average trading volume of 1,060,000 shares, the days-to-cover ratio is currently 1.0 days.

Vigil Neuroscience Trading Down 8.9 %

Vigil Neuroscience stock traded down $0.22 on Monday, reaching $2.21. 216,489 shares of the stock were exchanged, compared to its average volume of 1,485,211. The stock has a market cap of $90.14 million, a PE ratio of -1.07 and a beta of 1.84. The firm has a fifty day moving average price of $2.22 and a two-hundred day moving average price of $2.87. Vigil Neuroscience has a twelve month low of $1.49 and a twelve month high of $6.06.

Analysts Set New Price Targets

Several analysts have commented on the stock. Wedbush boosted their target price on shares of Vigil Neuroscience from $23.00 to $24.00 and gave the stock an "outperform" rating in a research report on Friday, November 8th. Guggenheim reiterated a "buy" rating on shares of Vigil Neuroscience in a report on Friday, January 24th. HC Wainwright restated a "buy" rating and set a $17.00 target price on shares of Vigil Neuroscience in a report on Thursday, January 23rd. William Blair started coverage on Vigil Neuroscience in a research note on Wednesday, December 4th. They set an "outperform" rating for the company. Finally, JMP Securities reissued a "market outperform" rating and issued a $22.00 price objective on shares of Vigil Neuroscience in a research note on Tuesday, November 26th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus target price of $19.75.

Hedge Funds Weigh In On Vigil Neuroscience

Large investors have recently made changes to their positions in the business. Point72 Asset Management L.P. increased its position in Vigil Neuroscience by 7.7% in the 3rd quarter. Point72 Asset Management L.P. now owns 1,600,000 shares of the company's stock worth $5,440,000 after buying an additional 115,000 shares during the period. 683 Capital Management LLC increased its position in Vigil Neuroscience by 14.8% during the fourth quarter. 683 Capital Management LLC now owns 1,400,000 shares of the company's stock worth $2,380,000 after acquiring an additional 180,420 shares during the period. Ensign Peak Advisors Inc grew its position in Vigil Neuroscience by 16.1% in the 4th quarter. Ensign Peak Advisors Inc now owns 703,116 shares of the company's stock worth $1,195,000 after purchasing an additional 97,580 shares during the last quarter. abrdn plc increased its holdings in shares of Vigil Neuroscience by 124.9% during the 4th quarter. abrdn plc now owns 528,472 shares of the company's stock worth $898,000 after purchasing an additional 293,461 shares during the period. Finally, Woodline Partners LP raised its position in shares of Vigil Neuroscience by 239.1% during the fourth quarter. Woodline Partners LP now owns 488,756 shares of the company's stock valued at $831,000 after buying an additional 344,614 shares during the last quarter. Institutional investors and hedge funds own 83.64% of the company's stock.

Vigil Neuroscience Company Profile

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.